medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2005, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2005; 4 (2)


Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease?

Raimondo G, Cacciamo G, Saitta C

Idioma: Ingles.
Referencias bibliográficas: 127
Paginas: 100-106
Archivo PDF: 76.52 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Pontisso P, Ruvoletto MG, Fattovich G, Chemello L, Gallorini A, Ruol A, Alberti A. Clinical and virological profiles in patients with multiple hepatitis infections. Gastroenterology 1993; 105: 1529-33.

  2. Sato S, Fujiyama S, Tanaka M, Yamasaki K, Kuramoto I, Kawano S, Sato T, et al . Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol 1994; 21: 159-166.

  3. Crespo J, Lozano JL, de la Cruz F, Rodrigo L, Rodriguez M, San Miguel G, Artinano E, et al . Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterology 1994; 89: 1147-51.

  4. Alberti A, Pontisso P, Chemello L, Alberti A, Pontisso P, Chemello L, Fattovich G, et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol 1995; 22(Suppl.1): 38-41.

  5. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, Tran van Nhiew J, et al . Characteristic of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 27-33.

  6. Liang TJ, Baruch Y, Ben-Porath E, Enat R, Bassan L, Brown NV, Rimon N, et al . Hepatitis B virus infection in patients with idiopathic liver disease. Hepatology 1991; 13: 1044-51.

  7. Zhang YY, Hansson BG, Kuo LS, Widell A, Nordenfelt E. Hepatitis B virus DNA in serum and liver is commonly found in Chinese patients with chronic liver disease despite the presence of antibodies to HBsAg. Hepatology 1993; 17: 538-544.

  8. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-26.

  9. Raimondo G, Balsano C, Craxì A, Farinati F, Levrero M, Mondelli M, Pollicino T, et al . Occult hepatitis B virus infection. Dig Liver Dis 2000; 32: 822-6.

  10. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult“? Hepatology 2001; 34: 194-203.

  11. Raimondo G. Occult HBV infection and liver disease: fact or fiction? J Hepatol 2001; 34: 471-473.

  12. Torbenson M & Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-486.

  13. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002; 9: 243-257.

  14. Mimms LT, Mosley JW, Hollinger FB, Aach RD, Stevens CE, Cunningham M, Vallari DV, et al . Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. Br Med J 1993; 307: 1095-1097.

  15. Sagnelli E, Coppola N, Messina V, Di Caprio D, Marrocco C, Marotta A, Onofrio M, et al . HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002; 36: 1285-1291.

  16. Ganem D, Prince AM. Hepatitis B virus infection - Natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.

  17. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxì A, Farinati F, et al . Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102-10.

  18. Wieland SF, Spangenberg HC, Thimme R, Purcell RH, Chisari FV. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci USA 2004: 1001: 2129-34.

  19. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, et al . Persistence of cccDNA during the natural history of chronic hepatitis B and decline during Adefovir-Dipivoxil therapy. Gastroenterolgy 2004; 126: 1750-58.

  20. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004; 127(5 Suppl 1): S56-61.

  21. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1): S72-8.

  22. Hillman MR. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 2001; 19: 1837-1848.

  23. Stuver SO. Towards global control of liver cancer? Semin Cancer Biol 1998; 8: 299-306.

  24. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002; Aug83(Pt 8): 2059-73.

  25. Arauz-Ruiz P, Norder H, Visona KA, Magnius LO. Genotype F prevails in HBV infected patients of hispanic origin in Central America and may carry the precore stop mutant. J Med Virol 1997; 51: 305-12.

  26. Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology 2002; 35: 1274-6.

  27. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; Sep 9; 2: 588-91.

  28. Brunetto MR, Stamler M, Schodel F, Will H, Ottobrelli A, Rizzetto M, Verme G, et al . Identification of HBV variants which cannot produce precore derived HBeAg and may be responsible for severe hepatitis. Ital J Gastroenterol 1989; 21: 151-154.

  29. Raimondo G, Costantino L, Caccamo G, Pollicino T, Squadrito G, Cacciola I, Brancatelli S. Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases. J Hepatol 2004; 40: 515-519.

  30. Santantonio T, Jung MC, Pastore G, Angarano G, Gunther S, Will H. Familial clustering of HBV pre-C and pre-S mutants. J Hepatol 1997; 26: 221-7.

  31. Pollicino T, Zanetti AR, Cacciola I, Petit MA, Smedile A, Campo S, Sagliocca L, et al . Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. Hepatology 1997; 26: 495-9.

  32. Le Seyec J, Chouteau P, Cannie I, Guguen-Guillouzo C, Gripon P. Role of the pre-S2 domain of the large envelope protein in hepatitis B virus assembly and infectivity. J Virol 1998; 72: 5573-8.

  33. Fan YF, Lu CC, Chen WC, Yao WJ, Wang HC, Chang TT, Lei HY, et al . Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 2001; 33: 277-86.

  34. Blum H, Galun E, Liang TJ, von Weizsacker F, Wands JR. Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication. J Virol 1991; 65: 1836-42.

  35. Yamamoto K, Horikita M, Tsuda F, Itoh K, Akahane Y, Yotsumoto S, Okamoto H, et al . Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 1994; 68: 2671-76.

  36. Carman WF, Van Deursen FJ, Mimms LT, Hardie D, Coppola R, Decker R, Sanders R. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa and Sardinia. Hepatology 1997; 26: 1658-66.

  37. Figus A, Blum HE, Vyas GN, De Virgilis S, Cao A, Lippi M, Lai E, et al . Hepatitis B viral nucleotide sequences in non-A, non-B or hepatitis B virus related chronic liver disease. Hepatology 1984; 4: 364-368.

  38. Thiers V, Nakajima E, Kremsdorf D, Mack D, Schellekens H, Driss F, Goudeau A, Wands J, Sninsky J, Tiollais P, et al . A transmission of hepatitis B from hepatitis B seronegative subjects. Lancet 1988; 2: 1273-76.

  39. Kaneko S, Miller RH, Feinstone SM, Unoura M, Kobayashi K, Hattori N, Purcell RH. Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci 1989; 86: 312-316.

  40. Wang JT, Wang TH, Sheu JC, Shih LN, Lin JT, Chen DS. Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen. J Infect Dis 1991; 163: 397-399.

  41. Liang TJ, Blum HE, Wands JR. Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers. Hepatology 1990; 12: 204-212.

  42. Loriot MA, Marcellin P, Bismuth E, Martinot-Peignoux M, Boyer N, Degott C, Erlinger S, et al . Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs sieroconversion in patients with chronic hepatitis B. Hepatology 1992; 15: 32-36.

  43. Zhang Y-Y, Hansson BG, Kuo LS, Widell A, Nordenfelt E. Hepatitis B virus DNA in serum and liver is commonly found in Chinese patients with chronic liver disease despite the presence of antibodies to HBsAg. Hepatology 1993; 17: 538-544.

  44. He C, Nomura F, Itoga S, Isobe K, Nakai T. Prevalence of vaccine-induced escape mutants of hepatitis B virus in the adult population in China: a prospective study in 176 restaurant employees. J Gastroenterol Hepatol 2001; 16: 1373-7.

  45. Lu M, Lorentz T. De novo infection in a renal transplant recipient caused by novel mutants of hepatitis B virus despite the presence of protective anti-hepatitis B surface antibody. J Infect Dis 2003; 187: 1323-6.

  46. Basuni AA, Butterworth L, Cooksley G, Locarnini S, Carman WF. Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries. Vaccine 2004; 29: 2791-9.

  47. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, et al . Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-7.

  48. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, et al . Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 1078-88.

  49. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, et al . Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.

  50. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, et al . Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 748-55.

  51. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, et al . Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-7.

  52. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, Gibbs CS, et al . Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-9.

  53. Werle B, Cinquin K, Marcellin P, Pol S, Maynard M, Trepo C, Zoulim F. Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. J Viral Hepat 2004; 11: 74-83.

  54. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, Gojobori T, et al . Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 1998; 143: 2493-503.

  55. Penin F. Structural biology of hepatitis C virus. Clin Liv Dis 2003; 7: 1-22.

  56. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.

  57. Di Bisceglie AM, McHutchison J, Rice CM. New therapeutic strategies for hepatitis C. Hepatology 2002; 35: 224-231.

  58. Thomson M, Liang TJ. Molecular biology of hepatitis C virus. In: Hepatitis C. Edited by TJ Liang and J Hoofnagle. Boston: Academic Press 2000: 1-23.

  59. Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 2003; 7: 45-66.

  60. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001; 33: 321-327.

  61. Troisi CL, Hollinger FB, Hoots WK, et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993; 81: 412-418.

  62. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24 Suppl 2: 3-8.

  63. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-100.

  64. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999; 31 (Suppl 1): 17-24.

  65. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26 (Suppl 1): 34S-38S.

  66. Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol 1999; 31 (Suppl 1:) 25-30.

  67. Agnello V, De Rosa FG. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 2004; 40: 341-52.

  68. Zignego AL, Brechot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol 1999; 31: 369-76.

  69. Hadziyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepat 1997; 4: 9-28.

  70. Di Marco V, Lojacono O, Cammà C, Vaccaio A, Giunta M, Martorana G, Fuschi P, et al . The long-term course of chronic hepatitis B. Hepatology 1999; 30: 257-264.

  71. Guptan RC, Thakur V, Raina V, Sarin SK. Alpha-Interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. J Gastroenterol Hepatol 1999; 14: 893-898.

  72. Squadrito G, Orlando ME, Pollicino T, Raffa G, Restuccia T, Cacciola I, Di Marco V, et al . Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. Am J Gastroenterol 2002; 97: 1518-1523.

  73. Gaeta GB, Stornaiuolo G, Precone DF, Lobello S, Chiaramonte M, Stroffolini T, Colucci G, et al . Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 2003; 39: 1036-41.

  74. Fong TL, Di Bisceglie AM, Waggoner JG, Banks SM, Hoofnagle JH. The significance of antibody hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991; 14: 64-67.

  75. Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995; 22: 1101-1108.

  76. Sagnelli E, Coppola N, Scolastico C, Filippini P, Santantonio T, Stroffolini T, Piccinino F. Virological and clinical aspects of reciprocal inhibitory effect of hepatitis B, C, and Delta viruses in patients with chronic hepatitis. Hepatology 2000; 32: 1106-1110.

  77. Seeff LB. Natural history of chronnic hepatitis C. Hepatology 2002; 36: S35-S46.

  78. Simonetti RG, Cammà C, Fiorello F, Cottone M, Rapicetta M, Marino L. Hepatitis C virus infection and a risk factor for hepatocellular carcinoma in patients with cirrhosis. Ann Intern Med 1992; 116: 97-102.

  79. Benvegnù L, Fattovich G, Noventa F, Tremolada F, Chemello L, Cecchetto A, Alberti A. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994; 74: 2442-2448.

  80. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, Lobello S, et al . Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85: 2132-2137.

  81. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36: S74-S83.

  82. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75: 347-354.

  83. Tanaka H, Tsukuma H, Yamano H, Oshima A, Shibata H. Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus. Int J Cancer 2004; 112: 1075-1080.

  84. Strader DB. Understudied populations with hepatitis C. Hepatology 2002; 36: S226-S236.

  85. Weltman MD, Brotodihardjo A, Crewe EB, Farrell GC, Bilous M, Grierson JM, Liddle C. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995; 2: 39-45.

  86. Mazzella G, Saracco G, Festi D, Rosina F, Marchetto S, Jaboli F, Sostegni R, et al . Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastoenterol 1999; 94: 2246-2250.

  87. Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, Cremonini C, et al . High doses of á-Interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long-term results of a prospective randomized trial. Am J Gastroenterol 2001; 96: 2973-2977.

  88. Villa E, Grottola A, Trande P, Seium Y, Rebecchi AM, Dugani A, Manenti F. Reactivation of hepatitis B virus infection induced by Interferon (IFN) in HBsAg-positive, antiHCV-positive patients. Lancet 1993; 341: 1413.

  89. Liu CJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and Interferon is effective for hepatitis C virus clearence in hepatitis B and C dually infected patients. Hepatology 2003; 37: 568-576.

  90. Fattovich G, Tagger A, Brollo L, Giustina G, Pontisso P, Realdi G, Alberti A, et al . Hepatitis virus infection in chronic hepatitis B virus carriers. J Infect Dis 1991; 163: 400-402.

  91. Sheen IS, Liaw YF, Chu CM, Pao CC. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearence during chronic hepatitis B virus infection. J Infect Dis 1992; 165: 831-834.

  92. Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol 1998; 36: 2084-2086.

  93. Jardi R, Rodriguez F, Buti M, Costa X, Cotrina M, Galimany R, Esteban R, et al. Rule of hepatitis B, C and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promotrer mutations on viral replicative interference. Hepatology 2001; 34: 404-410.

  94. Shih CM, Lo SJ, Miyamura T, Chen SY, Lee YH. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in Hu-H7 cells. J Virol 1993; 67: 5823-5832.

  95. Shih CM, Chen CM, Chen SY, Lee YH. Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation. J Virol 1995; 69: 1160-1171.

  96. Schuttler CG, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002; 37: 855-862.

  97. Chen SY, Kao CF, Chen CM, Shih CM, Hsu MJ, Chao CH, Wang SH, et al . Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 2003; 278: 591-607.

  98. Ohkawa K, Hayashi N, Yuki N, Hagiwara H, Kato M, Yamamoto K, Eguchi H, et al . Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients. J Hepatol 1994; 21: 509-514.

  99. Ohkawa K, Hayashi N, Yuki N, Masuzawa M, Kato M, Yamamoto K, Hosotsubo H, et al . Long-term follow up of hepatitis B virus and hepatitis C virus replicative levels in chronic hepatitis patients coinfected with both viruses. J Med Virol 1995; 46: 258-264.

  100. Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 1984; 86: 230-235.

  101. Davis GL, Hoofnagle JH. Reactivation of chronic type B hepatitis presenting as acute viral hepatitis. Ann Int Med 1985; 102: 762-765.

  102. Raimondo G, Rodinò G, Smedile V. Hepatitis B virus (HBV) markers and HBV-DNA in serum and liver tissue of patients with acute exacerbation of chronic type B hepatitis. J Hepatol 1990; 10: 271-273.

  103. Raimondo G, Schneider R, Stemler M, Smedile V, Rodino G, Will H. A new hepatitis B virus variant in a chronic carrier with multiple episodes of viral reactivation and acute hepatitis. Virology 1990; 179: 64-68.

  104. Arase Y, Ikeda K, Chayama K, Murashima N, Tsubota A, Suzuki Y, Saitoh S, et al . Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C. J Gastroenterol 2000; 35: 221-5.

  105. Halfon P, Bourliere M, Halimi G, Khiri H, Bertezene P, Portal I, Botta-Fridlund D, et al . Assessment of spontaneous fluctuations of viral load in untreated patients with chronic hepatitis C by two standardized quantitation methods: branched DNA and Amplicor Monitor. J Clin Microbiol 1998; 36: 2073-5.

  106. Pontisso P, Bellati G, Brunetto M, Chemello L, Colloredo G, Di Stefano R, Nicoletti M, et al . Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity? Hepatology 1999; 29: 585-9.

  107. Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, Squadrito G, et al . Wide spectrum of virological profiles in HBsAg/anti-HCV positive patients. An Italian multicentre study. J Hepatol 2005; 42 (Suppl. 2): 20 (Abstract).

  108. Villari D, Pernice M, Spinella S, Squadrito G, Rodino G, Brancatelli S, Longo G, et al . Chronic hepatitis in patients with active hepatitis B virus and hepatitis C virus combined infections: a histological study. Am J Gastroenterol 1995; 90: 955-958.

  109. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 94: 907.

  110. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, Chisari FV, et al . Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98: 1185-1194.

  111. Yotsuyanagi H, Yasuda K, Iino S, Moriya K, Shintani Y, Fujie H, Tsutsumi T, et al . Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 1998; 27: 1377-1382.

  112. Huo TI, Wu JC, Lee PC, Chau GY, Lui WY, Tsay SH, Ting LT, et al . Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998; 28: 231-236.

  113. Blackberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 2000; 33: 992-997.

  114. Michalak TI, Pardoe IU, Coffin CS, Churchill ND, Freake DS, Smith P, Trelegan CL. Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis. Hepatology 1999; 29: 928-938.

  115. Bergsland EK, Venook AP. Hepatocellular carcinoma. Curr Opin Oncol 2000; 12: 357-361.

  116. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745–750.

  117. Colombo M. Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis 1999; 19: 263–269.

  118. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36: S74-S83.

  119. Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. N Engl J Med 1981; 305: 1067-73.

  120. Paterlini P, Gerken G, Nakajima E, Terre S, D’Errico A, Grigioni W, Nalpas B, et al . Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl J Med 1990; 323: 80-85.

  121. Sheu JC, Huang GT, Shih LN, Lee WC, Chou HC, Wang JT, Lee PH, et al . Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology 1992; 103: 1322-27.

  122. Korba BE, Wells FV, Baldwin B, Cote PJ, Tennant BC, Popper H, Gerin JL. Hepatocellular carcinoma in woodchuck hepatitis virus infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology 1989; 9: 461-470.

  123. Marion PI. Ground squirrel hepatitis virus. In: McLachlan A, ed. Molecular biology of hepatitis B virus. Boca Raton: CRC, 1991: 39-51.

  124. Zignego AL, Fontana R, Puliti S, Barbagli S, Monti M, Careccia G, Giannelli F, et al. Relevance of inapparent co-infection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997; 51: 313–18.

  125. 125.De Maria N, Colantoni A, Idilman R, Friedlander L, Harig J, Van Thiel DH. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 2000; 95: 3529-36.

  126. Fukuda R, Ishimura N, Hanomoto S, Moritani M, Uchida Y, Ishihara S, Akagi S, et al . Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down regulation of type 1 interferon receptor gene expression in the liver. J Med Virol 2001; 63: 220-227.

  127. Raimondo G, Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection? Lancet 2005; 365: 638-640




2020     |     www.medigraphic.com